Focal Onset Seizures
📧 Sign up to get email alerts when something new happens for Focal Onset Seizures.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-03-13Clinical Trial Update: A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures [Phase 3]
A Phase 3 randomized trial evaluating XEN1101 versus placebo for focal onset seizures has completed.
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) [Phase 3]
Phase 3 randomized trial (X-TOLE3) comparing XEN1101 to placebo in focal onset seizures; enrollment is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-02-05Clinical Trial Update: Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy [Phase 2]
Phase 2 study of RAP-219 in adults with refractory focal epilepsy has completed, reporting on safety and efficacy outcomes.
-
CLINICAL_TRIALS trial_result · 2025-12-11Clinical Trial Update: An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures [Phase 2]
An open-label extension of CVL-865 evaluated as adjunctive therapy for focal onset seizures in a Phase 2 study; the trial was terminated and…
-
CLINICAL_TRIALS research · 2025-10-10Clinical Trial Update: SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures [Phase 2]
An open-label extension study of SPN-817 in adults with focal onset seizures is in Phase 2 and currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-07-03Clinical Trial Update: A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy [Phase 2]
Phase 2 study evaluating JNJ-40411813 in combination with levetiracetam or brivaracetam for focal onset seizures in epilepsy; the trial has …
-
CLINICAL_TRIALS trial_result · 2025-05-30Clinical Trial Update: A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures [Phase 2]
Phase 2 trial evaluating CVL-865 as adjunctive therapy for focal onset seizures has completed and results have been posted.
-
CLINICAL_TRIALS research · 2025-04-03Clinical Trial Update: An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures [Phase 2]
An open-label Phase 2 trial to evaluate the efficacy and safety of PRAX-628 in adults with focal onset seizures or primary generalized epile…
-
CLINICAL_TRIALS research · 2025-02-06Clinical Trial Update: RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures [Phase 2]
SPN-817 is being evaluated in a Phase 2 double-blind, placebo-controlled trial in adults with focal onset seizures. The study is currently r…
-
CLINICAL_TRIALS trial_result · 2025-01-23Clinical Trial Update: BOTOX Effects on Seizure Severity and Susceptibility [Phase 4]
A Phase 4 trial evaluating Botox (onabotulinumtoxinA) for effects on seizure severity and susceptibility in drug-resistant focal seizures wa…
-
CLINICAL_TRIALS trial_result · 2024-09-26Clinical Trial Update: A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures [Phase 2]
Phase 2 study assessing the effectiveness and safety of NBI-921352 when used with anti-seizure medications in adults with focal onset seizur…
-
CLINICAL_TRIALS trial_result · 2021-12-29Clinical Trial Update: Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy [Phase 2]
Phase 2 study evaluating padsevonil as adjunctive therapy for drug-resistant focal-onset seizures was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-10-25Clinical Trial Update: A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy [Phase 3]
Phase 3 trial evaluating padsevonil for drug-resistant focal-onset seizures was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-04-09Clinical Trial Update: Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy [Phase 2]
Phase 2 study evaluating padsevonil as an adjunctive treatment for drug-resistant focal-onset seizures completed with results posted in 2021…
-
FDA approval · 2020-08-31FDA Approved: XCOPRI — Supplemental Application (SK Life Science, Inc.)
The FDA approved a supplemental application for XCOPRI (cenobamate) submitted by SK Life Science, Inc., resulting in updated labeling.